Anzeige
Mehr »
Sonntag, 20.09.2026 - Börsentäglich über 12.000 News
114 Proben. 114 mit Gallium.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
VI

WKN: A2PM7K | ISIN: US92858K2042 | Ticker-Symbol:
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
VIVOS INC Chart 1 Jahr
5-Tage-Chart
VIVOS INC 5-Tage-Chart

Aktuelle News zur VIVOS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18.08.Vivos Inc. Achieves Two Major Operational Milestones: First IsoPet Shipments from New U.S. Production Facility and Authorization from India's Nuclear Regulatory Authority for International Manufacturing Center158Kennewick, WA, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy (PRnT) for the treatment of cancerous tumors, today announced...
► Artikel lesen
12.08.VIVOS INC - 10-Q, Quarterly Report1
27.07.Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update306Kennewick, WA, July 27, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy, is pleased to share this update on the meaningful advancements...
► Artikel lesen
VIVOS Aktie jetzt für 0€ handeln
06.07.Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel Precision Radionuclide Therapy446Kennewick, WA, July 06, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy (PRnT) for the treatment of cancerous tumors, is pleased...
► Artikel lesen
11.06.Vivos Inc. Announces Receipt of Washington State Radioactive Materials License for IsoPet Manufacturing240Kennewick, WA, June 11, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy (PRnT) for the treatment of cancerous tumors, is pleased...
► Artikel lesen
05.06.Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel Precision Radionuclide Therapy1
14.05.VIVOS INC - 10-Q, Quarterly Report1
17.02.Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites388Kennewick, WA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering its innovative RadioGel Radionuclide Therapy (PRnT) is preparing to open two new production...
► Artikel lesen
10.02.Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel Precision Radionuclide Therapy348Kennewick, WA, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy (PRnT) with its innovative RadioGel technology, today...
► Artikel lesen
06.11.25Vivos Inc. Issues Shareholder Update Letter270Kennewick, WA, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) - The Company continues to prioritize securing FDA Investigational Device Exemption (IDE) approval to initiate human clinical...
► Artikel lesen
29.10.25Vivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeutics262Kennewick, WA, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) today announced enhanced cooperation with Exubrion Therapeutics to advance the use of targeted radioactive isotope technology...
► Artikel lesen
29.09.25Vivos Inc.: Vivos Inc Board Authorizes Vivios Inc to Establish a Corporate Entity in India263Kennewick, WA, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) The Vivos Board granted authorization to form a wholly owned corporate subsidiary in India. Vivos Inc filed for the name...
► Artikel lesen
12 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1